Navigation Links
Echo Therapeutics Sends Response to Shareholder Letter
Date:9/5/2013

s and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:

Christine H. Olimpio                                  
Director, Investor Relations and Corporate Communications
(215) 717-4104                                         
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
2. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
3. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
4. AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
5. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
6. Oncology Therapeutics Market in India to 2018 Report
7. PTC Therapeutics Announces Achievement Of Major Milestone In SMA Collaboration
8. NuMe Health Becomes MicroBiome Therapeutics And Recruits New CEO
9. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
10. Sorrento Therapeutics Announces Reverse Split of Common Stock
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Cmed Technology , an eClinical ... and give a presentation about electronic data capture (EDC) ... Ops Executives ( SCOPE ) conference at Florida,s Westin ... As part of SCOPE,s two-day "Electronic Data In ...
... Ky., Feb. 4, 2011 MediVet-America, the leading ... animals suffering from osteoarthritis, hip dysplasia, ligament and ... year of business having achieved record advances in ... Adipose-Derived Stem Cell Procedure Kit and equipment, veterinary ...
... (Pink Sheets: AVXT ) ("AVAX" or the ... with the Securities and Exchange Commission ("SEC").  Upon the ... become a publicly reporting company.  The Company intends to ... Over-the-Counter Bulletin Board.  The Company,s Form 10, which contains ...
Cached Biology Technology:Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 3Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year 2AVAX Technologies, Inc. Files Form 10 With SEC 2
(Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
(Date:7/9/2014)... research has uncovered how a complex protein pivotal in ... is activated. The discovery answers a key question about ... which has been the subject of tens of thousands ... funding. , Jiazhen Zhang, a research student in Professor ... uncovered how the protein complex, called NF-κB, is activated. ...
(Date:7/9/2014)... associate professor of plant pathology and microbiology ... the 2014 Alexopoulos Prize by the Mycological ... the science of mycology the study of fungi ... plant pathogens, and medically important fungi. , The award ... mycologist. Stajich received the award last month in East ...
Breaking Biology News(10 mins):Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3Research reveals how key controller protein is switched on 2UC Riverside plant pathologist receives national recognition 2
... in a jetliner act and feel one way when crammed ... a different mindset when the middle seat is empty and ... parallel that exists among the proteins involved in health and ... issue of Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
... Georges Belfort has been recognized for his fundamental ... engineering. Belfort, the Russell Sage Professor of ... weeks received the 2011 Alan S. Michaels Award ... American Chemical Society (ACS) Biotechnology Division. ...
... A fascinating study published in the BMJ shows ... each week, as they drink daily, rather than more on ... disease than the Northern Irish. Ruidavets and colleagues compared groups ... have very different drinking cultures and rates of heart disease.The ...
Cached Biology News:Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award 2Pattern of drinking affects the relation of alcohol intake to coronary heart disease 2
...
Alexa Fluor 647 anti-mouse Qa-2...
... is ideal for developing single and multi-analyte ... contains the new, improved, and user friendly ... can design specific templates for commercial or ... integrated graphing and data regression capabilities; the ...
... The Luminex 100 Instrument System ... multi-analyte assays using Upstate's Beadlyte reagents. ... the Dell computer with software version ... Sheath Delivery System. Upstate offers $2000 ...
Biology Products: